Table 1:
Characteristics of adult SLK recipients with CKD prior to transplant from 2/27/02–12/31/2018
| Variable* | 18–39 N=202 |
40–49 N=413 |
50–59 N=1,221 |
60–64 N=752 |
65–69 N=465 |
70+ N=93 |
P-value |
|---|---|---|---|---|---|---|---|
| Male gender | 102 (50.5) | 264 (63.9) | 781 (64.0) | 481 (64.0) | 290 (62.4) | 57 (61.3) | 0.012 |
| Race/ethnicity | |||||||
| White | 145 (71.8) | 238 (57.6) | 699 (57.2) | 462 (61.4) | 319 (68.6) | 74 (79.6) | <0.001 |
| Black | 21 (10.4) | 62 (15.0) | 213 (17.4) | 118 (15.7) | 58 (12.5) | 2 (2.2) | |
| Hispanic | 28 (13.9) | 77 (18.6) | 242 (19.8) | 130 (17.3) | 65 (14.0) | 12 (12.9) | |
| Asian | 7 (3.5) | 22 (5.3) | 49 (4.0) | 29 (3.9) | 16 (3.4) | 4 (4.3) | |
| Other | 1 (0.5) | 14 (3.4) | 18 (1.5) | 13 (1.7) | 7 (1.5) | 1 (1.1) | |
| Etiology of liver disease | <0.001 | ||||||
| NASH/cryptogenic | 10 (5.0) | 55 (13.3) | 192 (15.7) | 197 (26.2) | 176 (37.8) | 45 (48.4) | |
| HCV | 23 (11.4) | 132 (32.0) | 575 (47.1) | 320 (42.6) | 136 (29.2) | 21 (22.6) | |
| Alcohol | 22 (10.9) | 92 (22.3) | 205 (16.8) | 106 (14.1) | 73 (15.7) | 9 (9.7) | |
| Autoimmune | 24 (11.9) | 27 (6.5) | 54 (4.4) | 41 (5.5) | 26 (5.6) | 13 (14.0) | |
| HBV | 6 (3.0) | 14 (3.4) | 38 (3.1) | 15 (2.0) | 7 (1.5) | 1 (1.1) | |
| PCLD/PCKD | 8 (4.0) | 30 (7.3) | 102 (8.4) | 40 (5.3) | 24 (5.2) | 0 (0.0) | |
| Other | 109 (54.0) | 63 (15.3) | 55 (4.5) | 33 (4.4) | 23 (4.9) | 4 (4.3) | |
| Diabetes | 27 (13.4) | 128 (31.0) | 536 (43.9) | 406 (54.0) | 252 (54.2) | 53 (57.0) | <0.001 |
| eGFR<30mL/min at transplant | 195 (96.5) | 366 (88.6) | 1,119 (91.7) | 680 (90.4) | 405 (87.1) | 82 (88.2) | 0.002 |
| Dialysis week prior to LT | 155 (77.1) | 277 (67.1) | 788 (64.6) | 476 (63.3) | 259 (55.7) | 45 (48.4) | <0.001 |
| Chronic dialysis | 97 (48.0) | 188 (45.5) | 509 (41.7) | 299 (39.8) | 142 (30.5) | 26 (28.0) | <0.001 |
| Days on chronic dialysis | 655 (330–1,311) | 564 (219–1,164) | 460 (174–1,068) | 439 (136–1,237) | 495 (195–915) | 169 (49–661) | <0.001 |
| Prior transplant | 30 (14.9) | 31 (7.5) | 90 (7.4) | 46 (6.1) | 18 (3.9) | 4 (4.3) | <0.001 |
| BMI | 23.0 (20.7, 27.9) | 26.0 (23.0, 30.2) | 26.5 (23.5, 30.7) | 26.7 (23.5, 30.8) | 26.6 (23.6, 30.4) | 26.9 (23.5, 31.5) | <0.001 |
| Bilirubin | 1.1 (0.5, 4.0) | 1.5 (0.7, 4.0) | 1.6 (0.8, 3.9) | 1.6 (0.8, 4.0) | 1.6 (0.8, 3.4) | 2.2 (1.1, 5.4) | 0.002 |
| INR | 1.2 (1.1, 1.6) | 1.4 (1.2, 1.8) | 1.4 (1.2, 1.8) | 1.4 (1.2, 1.9) | 1.4 (1.2, 1.8) | 1.5 (1.3, 1.9) | <0.001 |
| MELD exception type | <0.001 | ||||||
| No exception | 133 (65.8) | 327 (79.2) | 974 (79.8) | 574 (76.3) | 343 (73.8) | 75 (80.7) | |
| HCC exception | 2 (1.0) | 13 (3.2) | 112 (9.2) | 106 (14.1) | 73 (15.7) | 15 (16.1) | |
| Non-HCC exception‡ | 67 (33.2) | 71 (17.7) | 135 (11.1) | 72 (9.6) | 49 (10.5) | 3 (3.2) | |
| Laboratory MELD score | 24 (21–30) | 24 (21–31) | 24 (21–30) | 25 (21–31) | 24 (21–30) | 26 (21–33) | 0.57 |
| Allocation MELD score | 30 (25–35) | 27 (23–32) | 27 (23–33) | 28 (24–33) | 28 (24–33) | 29 (24–34) | <0.001 |
| Functional status** | 0.002 | ||||||
| No impairment | 49 (24.3) | 85 (20.6) | 201 (16.5) | 116 (15.4) | 86 (18.5) | 15 (16.1) | |
| Mild impairment | 77 (38.1) | 180 (43.6) | 493 (40.4) | 339 (45.1) | 199 (42.8) | 39 (41.9) | |
| Moderate to severe impairment | 58 (28.7) | 127 (30.8) | 458 (37.5) | 266 (35.4) | 165 (35.5) | 38 (40.9) | |
| Missing | 18 (8.9) | 21 (5.1) | 69 (5.7) | 31 (4.1) | 15 (3.2) | 1 (1.1) | |
| Donor KDRI | 1.0 (0.9, 1.2) | 1.0 (0.9, 1.3) | 1.1 (0.9, 1.3) | 1.1 (0.9, 1.3) | 1.1 (0.9, 1.4) | 1.1 (0.9, 1.4) | <0.001 |
| Donor KDPI | 0.27 (0.12, 0.45) | 0.31 (0.13, 0.51) | 0.33 (0.15, 0.57) | 0.32 (0.14, 0.56) | 0.37 (0.17, 0.59) | 0.39 (0.19, 0.65) | 0.002 |
| Donor LDRI | 1.22 (1.09, 1.40) | 1.24 (1.10, 1.45) | 1.26 (1.11, 1.51) | 1.27 (1.10, 1.51) | 1.30 (1.14, 1.52) | 1.28 (1.11, 1.54) | 0.049 |
| Donor age | 28.0 (20.0, 41.0) | 35.0 (23.0, 46.0) | 35.0 (24.0, 48.0) | 33.0 (24.0, 46.5) | 35.0 (24.0, 50.0) | 39.0 (26.0, 49.0) | <0.001 |
Abbreviations: NASH=nonalcoholic steatohepatitis; HCV=hepatitis C virus; HBV=hepatitis B virus; PCLD=polycystic liver disease; PCKD=polycystic kidney disease; LT=liver transplant; BMI=body mass index; KDRI=kidney donor risk index; KDPI=kidney donor profile index; LDRI=liver donor risk index
Categorical data as: Number (%); continuous data reported as: median (IQR)
Primary sclerosing cholangitis, primary biliary cholangitis, or autoimmune hepatitis. Includes exceptions for symptoms of liver disease (eg, refractory ascites), polycystic liver disease, and metabolic conditions.
Functional status based on Karnofsky score data in the OPTN/UNOS database; no impairment: 80–100%; mild impairment: 50–70%; moderate to severe impairment: 10–40%